Fla. Admin. Code Ann. R. 64E-5.622 - Release of Patients or Human Research Subjects Treated with Radiopharmaceuticals, Implants or Remote Afterloader Units
(1) Except as authorized by subsection
64E-5.622(4), F.A.C., a licensee shall not authorize release from confinement
for medical care any patient administered a radiopharmaceutical until:
(a) The dose rate from the patient is less
than 5 millirems (50 µSv) per hour at a distance of 1 meter; or
(b) The activity in the patient is less than
30 millicuries (1.11 GBq).
(2) Except as authorized by subsection
64E-5.622(4), F.A.C., a licensee shall not authorize release from confinement
for medical care any patient administered a permanent implant until the dose
rate from the patient is less than 5 millirems (50 µSv) per hour at a
distance of 1 meter.
(3)
Immediately after removing the last temporary implant source from a patient,
the licensee shall make a radiation survey of the patient with a radiation
survey instrument to confirm that all sources have been removed. The licensee
shall not release a patient treated by temporary implant from confinement for
medical care until all sources have been removed.
(4) Licensees and license applicants whose
proposed procedures to release individuals who have been administered
radiopharmaceuticals or permanent implants containing radioactive material from
the control of licensees differ from those specified in subsections (1) and
(2), above, must submit their proposed procedures to the department for
approval. The procedures must:
(a)
Demonstrate that the total effective dose equivalent to any other individual
from exposure to the released individual is not likely to exceed 500 millirem
(5 µSv);
(b) Contain a copy
of the instructions including written instructions to be given to the released
individual, or the individual's parent or guardian, on actions recommended to
maintain doses to other individuals as low as is reasonably achievable if the
total effective dose equivalent to another individual is likely to exceed 100
millirem (1 µSv). If the dose to a breast-feeding infant or child could
exceed 100 millirem (1 µSv) if there were no interruption of
breast-feeding, the instructions also shall include:
1. Guidance on the interruption or
discontinuance of breast-feeding, and
2. Information on the consequences of failing
to follow the guidance.
(c) Specify that the licensee shall maintain
a record of the basis for authorizing the release of an individual from their
control who has been administered radiopharmaceuticals or permanent implants
containing radioactive material for 3 years after the date of
release.
(5) A licensee
shall maintain a record of patient surveys which demonstrates compliance with
subsections 64E-5.622(3) and (6), F.A.C., for 3 years. Each record shall
include the date of the survey, the name of the patient, the dose rate from the
patient expressed as millirems (microsieverts) per hour and measured within 1
meter from the patient, and the initials of the individual who performed the
survey.
(6) Before releasing a
patient or human research subject from licensee control, a licensee shall
survey the patient or the human research subject and the remote afterloader
unit with a portable radiation detection survey instrument to confirm that the
source(s) has been removed from the patient or human research subject and
returned to the safe shielded position.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.